MOBIDIAG
1.3.2021 07:02:07 CET | Business Wire | Press release
Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.
These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The Amplidiag® RESP-4 assay can rapidly and simultaneously determine an accurate diagnosis from one patient sample using nasopharyngeal swabs, helping to guide clinicians to the relevant treatment decision for each patient. The test runs on the Mobidiag Amplidiag® Easy platform , which provides clinicians with an optimized sample screening process, with automated DNA/RNA extraction and PCR plate setup. Based on well-established high-throughput PCR technology, the platform can process 46 samples in approximately three hours.
This new test further broadens Mobidiag’s already available portfolio of diagnostics tests.
Tuomas Tenkanen, CEO of Mobidiag said, “We are very pleased to announce the CE-IVD marking for the Amplidiag® RESP-4 assay, which is highly relevant to both the traditional flu season and COVID-19. Symptoms caused by these viruses [SARS-CoV-2, Influenza A, Influenza B and RSV] can be very similar, and it is imperative that healthcare professionals are able to rapidly distinguish between them, in order to start the appropriate treatment for the benefit of patients.
In response to the growing need for fast and reliable diagnostics, at Mobidiag we are putting all our efforts into maintaining a high degree of autonomy in the production of our Amplidiag® tests by securing critical components to provide continuous support for our customers, as we all work together to control the spread of COVID-19.”
Mobidiag is currently developing Novodiag® RESP-4, a molecular diagnostic test using its Novodiag® platform for the rapid and on-demand detection of SARS-CoV-2, Influenza A, Influenza B and RSV. This test will complement Amplidiag® RESP-4 and enable clinicians to detect respiratory viruses to support early decisions in managing efficiently epidemiological and infection control measures, isolate patients in a timely manner, and ultimately improve patient care and outcomes.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you have any symptoms of respiratory infections.
Notes to editors
About Mobidiag Ltd
Mobidiag is a fast-growing molecular diagnostics company whose rapid, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210228005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Measuring Muscles with Quantitative MRI: New Study Published in Neurology Expands the Evidence for Using MRI Biomarkers in SBMA26.8.2026 14:27:00 CEST | Press release
AMRA Medical is pleased to announce the publication of new research in Neurology demonstrating the potential of quantitative whole-body MRI to measure disease progression in Spinal and Bulbar Muscular Atrophy (SBMA), a rare, progressive neuromuscular disease. The research was also selected for the cover of the issue, providing additional visibility for this important work in neuromuscular disease research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826386576/en/ AMRA Medical - Measuring Muscles with Quantitative MRI The manuscript, titled “Muscle MRI as an imaging biomarker of muscle damage in patients with spinal and bulbar muscular atrophy” highlights how MRI-based muscle composition biomarkers can provide sensitive and objective measures of disease-related change over time. With AMRAⓇ Researcher, the study evaluated 25 participants with SBMA to investigate the ability of fat-referenced MRI to assess changes in musc
KEWPIE IT. London discovers the Mayo behind the Iconic Tamago Sando26.8.2026 14:10:00 CEST | Press release
KEWPIE MAYONNAISE launches new campaign celebrating the simple ingredient that transforms an everyday Egg Sandwich into something memorable. What makes the Tamago Sando so extraordinary? The answer is simple: KEWPIE IT. Covent Garden Piazza, London, 19-20 September 2026 Kewpie Corporation(TOKYO:2809) is inviting Londoners to discover how one simple squeeze can transform one of the world's most iconic sandwiches. Through a new experiential pop-up in Covent Garden Piazza, the iconic Japanese mayonnaise brand is bringing its rich, creamy, umami flavour to the heart of London's food scene, celebrating the ingredient that elevates the Tamago Sando AKAthe iconic Japanese Egg Sandwich. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826081552/en/ An image of the pop-up scheduled to take place at Covent Garden Piazza in London KEWPIE MAYONNAISE is mostly made with egg yolks (not whole eggs), which is responsible for its richness a
NetApp Named a Leader in the 2026 Gartner® Magic Quadrant™ for Enterprise Storage Platforms26.8.2026 14:00:00 CEST | Press release
NetApp is ranked first in the Hybrid Cloud Storage Use Case in the 2026 Gartner® Critical Capabilities for Enterprise Storage Platforms NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Storage Platforms, continuing to acknowledge NetApp as a Leader in this market from its inaugural edition of this report in 2025. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. Additionally, the 2026 Gartner Critical Capabilities for Enterprise Storage Platforms report ranks NetApp first in the Hybrid Cloud Storage Use Case and second in the Hybrid Platform Services Use Case. NetApp believes this recognition validates the company’s ability to help customers address their most pressing data challenges while offering more predictable hardware delivery timelines than its competitors. The NetApp Pl
Copeland Appoints Sandro Matic as President, Americas, and Gwen Cheramy as President, Europe26.8.2026 14:00:00 CEST | Press release
Leadership appointments support continuity and execution across Copeland's global operations Copeland, a global provider of compression technologies and controls solutions, today announced that Gwen Cheramy will join the company as President of its Europe business on Oct. 1, 2026, and that Sandro Matic will assume the role of President of its Americas business on Sept. 1, 2026. Matic will continue to lead Europe on an interim basis until Cheramy joins Copeland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826567313/en/ Sandro Matic, President, Americas for Copeland "Sandro and Gwen are both proven leaders with strong track records of delivering results within our industry,” said Ross B. Shuster, CEO of Copeland. "In their new roles, they will be instrumental in providing leadership to our local colleagues, supporting our customers, and advancing Copeland’s strategic priorities across their respective regions while helpi
Pure Lithium Announces Unprecedented Cycling Results From ItsAdvanced Anode™ Lithium Metal Battery Technology26.8.2026 13:00:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, today announced that our Advanced Anode™ battery, technology developed specifically to enable ultra-long cycling, has achieved more than 9,315 cycles. The cells continue to cycle in the Company's laboratory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826201214/en/ To the Company’s knowledge, no other lithium metal battery in development has achieved such results under equivalent testing conditions. The performance of the Company’s battery, achieved with negligible capacity fade, far exceeds today’s commercial lithium-ion battery cycling requirements across numerous applications, where performance typically ranges from 250 to 2,000 cycles, depending on the application. These results were achieved at 100% depth of discharge, and charge rates of 1C: 1C.1 “The results of Pure Lithium’s cycling performance are disruptive. Cycle life
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom